全文获取类型
收费全文 | 26586篇 |
免费 | 1860篇 |
国内免费 | 238篇 |
专业分类
耳鼻咽喉 | 414篇 |
儿科学 | 414篇 |
妇产科学 | 590篇 |
基础医学 | 3871篇 |
口腔科学 | 689篇 |
临床医学 | 2288篇 |
内科学 | 5043篇 |
皮肤病学 | 579篇 |
神经病学 | 1981篇 |
特种医学 | 1592篇 |
外科学 | 4325篇 |
综合类 | 281篇 |
一般理论 | 10篇 |
预防医学 | 1078篇 |
眼科学 | 658篇 |
药学 | 2330篇 |
1篇 | |
中国医学 | 270篇 |
肿瘤学 | 2270篇 |
出版年
2023年 | 131篇 |
2022年 | 117篇 |
2021年 | 705篇 |
2020年 | 387篇 |
2019年 | 662篇 |
2018年 | 718篇 |
2017年 | 593篇 |
2016年 | 687篇 |
2015年 | 1015篇 |
2014年 | 1254篇 |
2013年 | 1425篇 |
2012年 | 2128篇 |
2011年 | 2088篇 |
2010年 | 1289篇 |
2009年 | 1184篇 |
2008年 | 1625篇 |
2007年 | 1553篇 |
2006年 | 1449篇 |
2005年 | 1374篇 |
2004年 | 1240篇 |
2003年 | 1080篇 |
2002年 | 953篇 |
2001年 | 773篇 |
2000年 | 759篇 |
1999年 | 600篇 |
1998年 | 210篇 |
1997年 | 198篇 |
1996年 | 174篇 |
1995年 | 147篇 |
1994年 | 124篇 |
1993年 | 102篇 |
1992年 | 242篇 |
1991年 | 184篇 |
1990年 | 175篇 |
1989年 | 166篇 |
1988年 | 143篇 |
1987年 | 103篇 |
1986年 | 95篇 |
1985年 | 69篇 |
1984年 | 78篇 |
1983年 | 49篇 |
1982年 | 52篇 |
1981年 | 44篇 |
1980年 | 43篇 |
1979年 | 56篇 |
1978年 | 44篇 |
1977年 | 45篇 |
1974年 | 37篇 |
1972年 | 44篇 |
1971年 | 42篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献
2.
Kenny P. Pang FRCSEd FRCSI Claudio Vicini MD Filippo Montevecchi MD Ottavio Piccin MD MSc Sudipta Chandra MBBS MS Hyung C. Yang MD PhD Vikas Agrawal MS DLO Joseph C. K. Chung FRCS Yiong H. Chan BSc PhD Scott B. Pang Kathleen A. Pang Edward B. Pang Brian Rotenberg MD MPH FRCSC 《The Laryngoscope》2020,130(9):2281-2284
3.
Autoimmune comorbid diseases associated with lichen planus: a nationwide case–control study 下载免费PDF全文
4.
5.
6.
7.
Yoo Min Han Su Jin Chung Seokha Yoo Jong In Yang Ji Min Choi Jooyoung Lee Joo Sung Kim 《World journal of gastroenterology : WJG》2022,28(8):853-867
BACKGROUND Helicobacter pylori(H.pylori)infection is known to prevent the occurrence of gastroesophageal reflux disease(GERD)by inducing gastric mucosal atrophy.However,little is known about the relationship between atrophic gastritis(AG)and GERD.AIM To confirm the inverse correlation between AG and the occurrence and severity of GERD.METHODS Individuals receiving health checkups who underwent upper gastrointestinal endoscopy at Seoul National University Healthcare System Gangnam Center were included.The grade of reflux esophagitis was evaluated according to the Los Angeles classification.Endoscopic AG(EAG)was categorized into six grades.Serologic AG(SAG)was defined as pepsinogen I≤70 ng/m L and pepsinogen I/II ratio≤3.0.The association between the extent of EAG and SAG and the occurrence and severity of GERD was evaluated using multivariate logistic regression analysis.RESULTS In total,4684 individuals with GERD were compared with 21901 healthy controls.In multivariate logistic regression analysis,advanced age,male sex,body mass index>23 kg/m2,presence of metabolic syndrome,current smoking,and alcohol consumption were associated with an increased risk of GERD.Seropositivity for H.pylori immunoglobulin G antibodies was associated with a decreased risk of GERD.There was an inverse correlation between the extent of EAG and occurrence of GERD:Odds ratio(OR),1.01[95%confidence interval(CI):0.90-1.14]in C1,0.87(0.78-0.97)in C2,0.71(0.62-0.80)in C3,0.52(0.44-0.61)in O1,0.37(0.29-0.48)in O2,and 0.28(0.18-0.43)in O3.Additionally,the extent of EAG showed an inverse correlation with the severity of GERD.The presence of SAG was correlated with a reduced risk of GERD(OR=0.49,95%CI:0.28-0.87,P=0.014).CONCLUSION The extent of EAG and SAG exhibited strong inverse relationships with the occurrence and severity of GERD.AG followed by H.pylori infection may be independently protect against GERD. 相似文献
8.
9.
Micro‐evolution of the hepatitis B virus genome in hepatitis B e‐antigen‐positive carriers: Comparison of genotypes B and C at various immune stages 下载免费PDF全文
10.
Miju Bae Sung Woon Chung Chung Won Lee Up Huh Min Su Kim Seung Hwan Song 《Asian journal of surgery / Asian Surgical Association》2019,42(1):235-239